|
1) Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008; 6: 379-88
|
|
|
|
2) Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun. 2008; 30: 5-11
|
|
|
|
|
|
3) Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol. 2008; 14: 3306-12
|
|
|
|
|
|
4) Vergani D, Mieli-Vergani G. The impact of autoimmunity on hepatocytes. Semin Liver Dis. 2007; 27: 140-51
|
|
|
|
|
|
5) Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008; 48: 140-7
|
|
|
|
|
|
6) Tahiri F, Le Naour F, Huguet S, et al. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology. 2008; 47: 937-48
|
|
|
|
|
|
7) Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4＋CD25＋ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006; 176: 4484-91
|
|
|
|
|
|
8) Sakaki M, Hiroishi K, Baba T, et al. Intrahepatic status of regulatory T cells in autoimmune liver diseases and chronic viral hepatitis. Hepatol Res. 2008; 38: 354-61
|
|
|
|
|
|
9) Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48: 169-76
|
|
|
|
|
|
10) Yatsuji S, Hashimoto E, Kaneda H, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful？ J Gastroenterol. 2005; 40: 1130-8
|
|
|
|
|
11) Lu F, Xia Q, Ma Y, et al. Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis. Biochem Biophys Res Commun. 2008; 367: 284-90
|
|
|
|
|
|
12) Ishibashi H, Komori A, Shimoda S, et al. Guidelines for therapy of autoimmune liver disease. Semin Liver Dis. 2007; 27: 214-26
|
|
|
|
|
|
13) Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007; 102: 1005-12
|
|
|
|
|
|
14) Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007; 46: 1138-45
|
|
|
|
|
|
15) Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 202-14
|
|
|
|
|
|
16) Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007; 37 Suppl 3: S462
|
|
|
|
|
|
17) Peters MG, Di Bisceglie AM, Kowdley KV, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology. 2007; 46: 769-75
|
|
|
|
|
|
18) Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007; 46: 785-92
|
|
|
|
|
|
19) Juran BD, Atkinson EJ, Schlicht EM, et al. Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology. 2008; 47: 563-70
|
|
|
|
|
|
20) Shimoda S, Harada K, Niiro H, et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology. 2008; 47: 958-65
|
|
|
|
|
|
21) Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 2006; 43: 729-37
|
|
|
|
|
|
22) Haliloglu N, Erden A, Erden I. Primary biliary cirrhosis: Evaluation with T2-weighted MR imaging and MR cholangiopancreatography. Eur J Radiol. 2008; (in press)
|
|
|
|
|
|
23) Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med. 2007; 357: 1524-9
|
|
|
|
|
|
24) Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008; 38: 557-64
|
|
|
|
|
|
25) Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007; 46: 776-84
|
|
|
|
|
|
26) Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant. 2006; 20: 211-20
|
|
|
|
|
|
27) Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007; 45: 118-27
|
|
|
|
|
|
28) Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007; 102: 1244-50
|
|
|
|
|
|
29) Chazouilleres O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006; 44: 400-6
|
|
|
|
|